BiotechTube
Home/Aurealis Therapeutics/Juha Yrjänheikki
JY

Juha Yrjänheikki

CEO

Aurealis Therapeutics

Therapeutic Areas

Chronic WoundsOncologyInflammatory Diseases

Aurealis Therapeutics Pipeline

DrugIndicationPhase
AUP-16Chronic Diabetic Foot Ulcers (DFU)Phase 2
AUP-55Solid Tumors (Ovarian, Peritoneal, Bladder, Recurrent Melanoma)Pre-clinical/Phase 1

Leadership Team at Aurealis Therapeutics

LD
Laurent Décory
COO
MP
Matleena Piiroinen
Drug Safety Officer
View full Aurealis Therapeutics profile